Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy – Intellia Therapeutics

Written by

admin

in

  1. Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy  Intellia Therapeutics
  2. Intellia’s gene therapy shows sustained TTR reduction in ATTR patients  Investing.com
  3. Intellia Therapeutics’ Promising Clinical Trial Results and Competitive Positioning in Gene-Editing Therapies  TipRanks
  4. Intellia Therapeutics to Present Long-Term Data on Investigational Nex-z for ATTR Amyloidosis at International Conference in Italy  Quiver Quantitative
  5. Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy  Yahoo Finance

Continue Reading

More posts